

SWISS BIOTECH SUCCESS STORY



- Founded in 1997 by a small group of researchers and managers from Basel
- Active drug discovery and development organization
- More than 2,600 employees in over 30 affiliates reaching more than 50 markets*
- Part of the Johnson & Johnson Family of Companies since 2017
- Collaboration agreements with Idorsia Pharmaceuticals Ltd, Nippon Shinyaku, Bayer AG, Analytics for Life and ThirdPole Therapeutics

*2017



THE FOUNDING TEAM



Jean-Paul Clozel,
Martine Clozel,
Walter Fischli,
André J. Mueller, and
Thomas Widmann

THE CURRENT TEAM

Includes: Simon Eade, Martin Fichet, Nicholas Franco, Jane Griffiths, Alessandro Maresta, and Jürgen Scherer



KNOWLEDGE



- Leader in the science and medicine of pulmonary arterial hypertension (PAH), with over 20 years of experience in this devastating cardiovascular disorder
- Among the first to work in the field of endothelin receptor antagonists
- Focus also on orphan diseases



INDICATIONS

- PAH
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)**
- Digital Ulcers
- Niemann-Pick Type C
- Gaucher Disease

**approved in Brazil



PRODUCTS

- Tracleer®: compound acquired as "bosentan" from Roche as late stage drug candidate, developed clinically, approved and commercially available in over 60 markets including the US, EU and Japan
- Opsumit® (macitentan): second generation PAH treatment, resulted from a tailored drug discovery process by Actelion
- Upravi® (selexipag): PAH compound licensed ex-Japan in Phase 2 from Nippon Shinyaku, developed clinically, approved and commercially available in the US, EU, Japan, and many other markets
- Ventavis® (inhaled iloprost): PAH compound licensed in the US from Bayer AG via the acquisition of CoTherix in 2006
- Zavesca® (miglustat oral): first oral treatment option for type 1 Gaucher Disease, approved in the US and EU

SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Scientific break-through
- ★ Strong impact on society
- ★ Product approval and sustainable revenues
- ★ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland



Organized by

